Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs

Histone methylation and demethylation regulate B-cell development, and their deregulation correlates with tumor chemoresistance in diffuse large B-cell lymphoma, limiting cure rates. Since histone methylation status correlates with disease aggressiveness and relapse, we investigated the therapeutic potential of inhibiting histone 3 Lys27 demethylase KDM6B, in vitro, using the small molecule inhibitor GSK-J4. KDM6B is overexpressed in the germinal center B-cell subtype of diffuse large B-cell lymphoma, and higher KDM6B levels are associated with worse survival in patients with diffuse large B-cell lymphoma treated with R-CHOP. GSK-J4-induced apoptosis was observed in five (SU-DHL-6, OCI-Ly1, Toledo, OCI-Ly8, SU-DHL-8) out of nine germinal center B-cell diffuse large B-cell lymphoma cell lines. Treatment with GSK-J4 predominantly resulted in downregulation of B-cell receptor signaling and BCL6. Cell lines expressing high BCL6 levels or CREBBP/EP300 mutations were sensitive to GSK-J4. Our results suggest that B-cell receptor-dependent downregulation of BCL6 is responsible for GSK-J4-induced cytotoxicity. Furthermore, GSK-J4-mediated inhibition of KDM6B sensitizes germinal center B-cell diffuse large B-cell lymphoma cells to chemotherapy agents that are currently utilized in treatment regimens for diffuse large B-cell lymphoma.

• Publication year

  2017

• Venue

  Haematologica

• Publication date

  2017-02-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.3324/haematol.2016.144964PMID 27742770PMCID PMC5286945
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Aggressive Lymphomas

  2020cited by this paper
• JMJD3 promotes survival of diffuse large B-cell lymphoma subtypes via distinct mechanisms

  2016cited by this paper
• Targeting Wnt pathway in mantle cell lymphoma-initiating cells

  2015cited by this paper
• Temsirolimus inhibits cell growth in combination with inhibitors of the B-cell receptor pathway

  2015cited by this paper
• Genome engineering using CRISPR-Cas9 system.

  2015cited by this paper
• Polycomb genes, miRNA, and their deregulation in B-cell malignancies.

  2015cited by this paper
• Abstract 2673: Idelalisib has activity at clinically achievable drug concentrations in a subset of ABC and GCB diffuse large B-cell lymphoma and transformed follicular lymphoma cell lines

  2015cited by this paper
• An epigenetic view of B‐cell disorders

  2015cited by this paper
• Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBPα.

  2014cited by this paper
• Epstein-Barr Virus Down-Regulates Tumor Suppressor DOK1 Expression

  2014cited by this paper
• FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma

  2014cited by this paper
• Critical role of histone demethylase Jmjd3 in the regulation of CD4+ T cell differentiation

  2014cited by this paper
• A tour through the transcriptional landscape of platelets.

  2014cited by this paper
• The Histone Lysine Demethylase JMJD3/KDM6B Is Recruited to p53 Bound Promoters and Enhancer Elements in a p53 Dependent Manner

  2014cited by this paper
• PPISURV: a novel bioinformatics tool for uncovering the hidden role of specific genes in cancer survival outcome

  2014cited by this paper
• Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma

  2014cited by this paper
• Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma

  2014cited by this paper
• The B-Cell Receptor Is Required for Optimal Viability, Growth, and Chemotherapy Resistance of Diffuse Large B-Cell Lymphoma Cell Lines of the Germinal Center B-Cell Subtype

  2014cited by this paper
• Inhibition of demethylases by GSK-J1/J4

  2014cited by this paper
• Histone demethylase Jumonji D3 (JMJD3/KDM6B) at the nexus of epigenetic regulation of inflammation and the aging process

  2014cited by this paper
• A double take on bivalent promoters.

  2013cited by this paper
• DNA targeting specificity of RNA-guided Cas9 nucleases

  2013cited by this paper
• Long non-coding RNA ANRIL (CDKN2B-AS) is induced by the ATM-E2F1 signaling pathway.

  2013cited by this paper
• Genome engineering using the CRISPR-Cas9 system

  2013cited by this paper
• EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.

  2013cited by this paper
• The pathogenesis of Epstein-Barr virus persistent infection.

  2013cited by this paper
• DNA methylation profiling in human B cells reveals immune regulatory elements and epigenetic plasticity at Alu elements during B-cell activation

  2013cited by this paper
• Aberration in DNA Methylation in B-Cell Lymphomas Has a Complex Origin and Increases with Disease Severity

  2013cited by this paper
• Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma

  2013cited by this paper
• Epigenetic approaches for chemosensitization of refractory diffuse large B-cell lymphomas.

  2013cited by this paper
• Epigenomic evolution in diffuse large B-cell lymphomas

  2013cited by this paper
• The H3K27 demethylase JMJD3 is required for maintenance of the embryonic respiratory neuronal network, neonatal breathing, and survival.

  2012cited by this paper
• EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

  2012cited by this paper
• Epigenetic Regulation of B Lymphocyte Differentiation, Transdifferentiation, and Reprogramming

  2012cited by this paper
• Roles of BCL6 in normal and transformed germinal center B cells

  2012cited by this paper
• Histone H3K27me3 demethylases KDM6A and KDM6B modulate definitive endoderm differentiation from human ESCs by regulating WNT signaling pathway

  2012cited by this paper
• The H3K27me3 demethylase, KDM6B, is induced by Epstein–Barr virus and over-expressed in Hodgkin's Lymphoma

  2011cited by this paper
• SYK inhibition and response prediction in diffuse large B-cell lymphoma.

  2011cited by this paper
• Peptidyl prolyl isomerase, Pin1 is a potential target for enhancing the therapeutic efficacy of etoposide.

  2011cited by this paper
• The Role of NF-κB and H3K27me3 Demethylase, Jmjd3, on the Anthrax Lethal Toxin Tolerance of RAW 264.7 Cells

  2010cited by this paper
• BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis.

  2010cited by this paper
• A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo.

  2010cited by this paper
• BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.

  2010cited by this paper
• Aggressive lymphomas.

  2010cited by this paper
• BCL6 promoter interacts with far upstream sequences with greatly enhanced activating histone modifications in germinal center B cells

  2010cited by this paper
• Linking DNA methylation and histone modification: patterns and paradigms

  2009cited by this paper
• Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS.

  2009cited by this paper
• Origin and pathogenesis of nodular lymphocyte–predominant Hodgkin lymphoma as revealed by global gene expression analysis

  2008cited by this paper
• Coordinated regulation of transcriptional repression by the RBP2 H3K4 demethylase and Polycomb-Repressive Complex 2.

  2008cited by this paper
• Stromal gene signatures in large-B-cell lymphomas.

  2008cited by this paper
• BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt.

  2008cited by this paper
• Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas

  2008cited by this paper
• A bivalent chromatin structure marks key developmental genes in embryonic stem cells.

  2006cited by this paper
• High BCL6 expression predicts better prognosis, independent of BCL6 translocation status, translocation partner, or BCL6-deregulating mutations, in gastric lymphoma.

  2006cited by this paper
• Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.

  2005cited by this paper
• ONCOMINE: a cancer microarray database and integrated data-mining platform.

  2004cited by this paper
• Acetylation inactivates the transcriptional repressor BCL6

  2002cited by this paper
• Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

  2000cited by this paper
• Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation.

  1993cited by this paper
• A class of rank test procedures for censored survival data

  1982cited by this paper

• Structural landscape of H3K27me3 recognition by protein domains and their potential for inhibition.

  2026cites this paper
• Lysine demethylases 6 A and 6B as epigenetic regulators in therapeutic resistance of cancer

  2025cites this paper
• Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance

  2025cites this paper
• Lysine demethylase 6 (KDM6): A promising therapeutic target in autoimmune disorders and cancer.

  2025cites this paper
• Lysine demethylases and cancer.

  2025cites this paper
• Impact of Tyrosine Kinase Inhibitors on the Expression Pattern of Epigenetic Regulators

  2025cites this paper
• Interaction between stromal cells and tumor cells promotes the GCB-DLBCL cell survival via CD40/RANK-KDM6B-NF-κB axis.

  2025cites this paper
• Single-nuclei transcriptome analysis of IgM+ cells isolated from channel catfish (Ictalurus punctatus) spleen

  2025cites this paper
• Inhibiting H3K27 Demethylases Downregulates CREB‐CREBBP, Overcoming Resistance in Relapsed Acute Lymphoblastic Leukemia

  2025cites this paper
• Combined anti-leukemic effect of gilteritinib and GSK-J4 in FLT3-ITD+ acute myeloid leukemia

  2025cites this paper
• Targeting drug‐tolerant cells: A promising strategy for overcoming acquired drug resistance in cancer cells

  2023cites this paper
• KDM6B drives epigenetic reprogramming associated with lymphoid stromal cell early commitment and immune properties

  2023cites this paper
• Targeting lysine demethylase 6B ameliorates ASXL1 truncation–mediated myeloid malignancies in preclinical models

  2023cites this paper
• GSK-J4 Inhibition of KDM6B Histone Demethylase Blocks Adhesion of Mantle Cell Lymphoma Cells to Stromal Cells by Modulating NF-κB Signaling

  2023cites this paper
• Histone Demethylase Modulation: Epigenetic Strategy to Combat Cancer Progression

  2023cites this paper
• The role and prospect of lysine‐specific demethylases in cancer chemoresistance

  2023cites this paper
• The Role of CREBBP/EP300 and Its Therapeutic Implications in Hematological Malignancies

  2023cites this paper
• Targeting epigenetic regulators to overcome drug resistance in cancers

  2023cites this paper
• Epigenetic Alterations in Canine Malignant Lymphoma: Future and Clinical Outcomes

  2023cites this paper
• H3K27me3 Demethylase UTX Restrains Plasma Cell Formation

  2022cites this paper
• Impact of Histone Modifications and Their Therapeutic Targeting in Hematological Malignancies

  2022cites this paper
• lncNBAT1/APOBEC3A is a mediator of HBX-induced chemoresistance in diffuse large B cell lymphoma cells

  2022cites this paper
• H3K27me3 in Diffuse Midline Glioma and Epithelial Ovarian Cancer: Opposing Epigenetic Changes Leading to the Same Poor Outcomes

  2022cites this paper
• Hsa_circ_0000877 facilitates the progression of diffuse large B-cell lymphoma by miR-370-3p/mitogen-activated protein kinase kinase kinase kinase 4/Hippo pathway

  2022cites this paper
• JMJD family proteins in cancer and inflammation

  2022cites this paper
• Targeting histone methylation to reprogram the transcriptional state that drives survival of drug-tolerant myeloid leukemia persisters

  2022cites this paper
• Targeting histone demethylases as a potential cancer therapy (Review).

  2022cites this paper
• KDM6 Demethylases and Their Roles in Human Cancers

  2021cites this paper
• The Functions of the Demethylase JMJD3 in Cancer

  2021cites this paper
• KDM6B (JMJD3) and its dual role in cancer.

  2021cites this paper
• Treatment resistance in diffuse large B-cell lymphoma

  2021cites this paper
• Lysine Demethylases: Promising Drug Targets in Melanoma and Other Cancers

  2021cites this paper
• Migration and Adhesion of B-Lymphocytes to Specific Microenvironments in Mantle Cell Lymphoma: Interplay between Signaling Pathways and the Epigenetic Landscape

  2021influential citation
• Histone lysine demethylase inhibitor (HDMi) as chemo-sensitizing agent

  2021cites this paper
• Inhibition of H3K27me3 Demethylases Promotes Plasmablast Formation

  2021cites this paper
• Formation Inhibition of H3K27me3 Demethylases Promotes Plasmablast

  2021influential citation
• Histone Modifications and Their Targeting in Lymphoid Malignancies

  2021cites this paper
• Puerarin 6″‐O‐xyloside suppressed HCC via regulating proliferation, stemness, and apoptosis with inhibited PI3K/AKT/mTOR

  2020cites this paper
• KDM6B promotes activation of the oncogenic CDK4/6-pRB-E2F pathway by maintaining enhancer activity in MYCN-amplified neuroblastoma

  2020cites this paper
• The KDM Inhibitor GSKJ4 Triggers CREB Downregulation via a Protein Kinase A and Proteasome-Dependent Mechanism in Human Acute Myeloid Leukemia Cells

  2020cites this paper
• Can we use epigenetics to prime chemoresistant lymphomas?

  2020cites this paper
• AGGRESSIVE LYMPHOMAS: WHAT NOVEL APPROACHES ARE READY FOR PRIME TIME? Can we use epigenetics to prime chemoresistant lymphomas?

  2020cites this paper
• GSK-J4 induces cell cycle arrest and apoptosis via ER stress and the synergism between GSK-J4 and decitabine in acute myeloid leukemia KG-1a cells

  2020cites this paper
• Two old drugs, NVP-AEW541 and GSK-J4, repurposed against the Toxoplasma gondii RH strain

  2020cites this paper
• Oncogenic KRAS sensitizes lung adenocarcinoma to GSK-J4-induced metabolic and oxidative stress.

  2019cites this paper
• Targeting of Histone Demethylases KDM5A and KDM6B Inhibits the Proliferation of Temozolomide-Resistant Glioblastoma Cells

  2019cites this paper
• Antiproliferative effect of the histone demethylase inhibitor GSK‐J4 in chondrosarcomas

  2019cites this paper
• Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma

  2019cites this paper
• Assessment of epigenetic mechanisms and DNA double-strand break repair using laser micro-irradiation technique developed for hematological cells

  2019cites this paper
• Elevating H3K27me3 level sensitizes colorectal cancer to oxaliplatin

  2019cites this paper
• Epigenetic therapy in hematological cancers

  2019cites this paper
• Overexpression of miR-222-3p Promotes the Proliferation and Inhibits the Apoptosis of Diffuse Large B-Cell Lymphoma Cells via Suppressing PPP2R2A

  2019cites this paper
• JMJD3 in the regulation of human diseases

  2019cites this paper
• Biology and targeting of the Jumonji-domain histone demethylase family in childhood neoplasia: a preclinical overview

  2019cites this paper
• The role and prospect of JMJD3 in stem cells and cancer.

  2019cites this paper
• Is ultrasound combined with computed tomography useful for distinguishing between primary thyroid lymphoma and Hashimot's thyroiditis?

  2019cites this paper
• Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia

  2018cites this paper
• Targeting nucleolin for better survival in diffuse large B-cell lymphoma

  2018cites this paper
• Kdm6b is Required for Self-Renewal of Normal and Leukemic Mouse Stem Cells Under Proliferative Stress

  2018cites this paper
• Leveraging Epigenetics to Enhance the Cellular Response to Chemotherapies and Improve Tumor Immunogenicity

  2018cites this paper
• HBV infection potentiates resistance to S-phase arrest-inducing chemotherapeutics by inhibiting CHK2 pathway in diffuse large B-cell lymphoma

  2018cites this paper
• Epigenetic Targeting of Glioblastoma

  2018cites this paper
• JMJD3 facilitates C/EBPβ-centered transcriptional program to exert oncorepressor activity in AML

  2018cites this paper
• Forskolin Sensitizes Human Acute Myeloid Leukemia Cells to H3K27me2/3 Demethylases GSKJ4 Inhibitor via Protein Kinase A

  2018cites this paper
• The pharmacological role of histone demethylase JMJD3 inhibitor GSK-J4 on glioma cells

  2017cites this paper
• Is ultrasound combined with computed tomography useful for distinguishing between primary thyroid lymphoma and Hashimoto ’ s thyroiditis ? Running title : Application of ultrasound and computed tomography in differentiation of lymphoma and thyroiditis

  year unknowncites this paper